ArticlePharmacoepidemiology and drug safety2026
Oral Anticoagulant Use Among Older Adults in Long-Term Care Facilities: Trends Over Time and Impact of High-Risk Comorbidities.
Article in Pharmacoepidemiology and drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo examine oral anticoagulant (OAC) use in older adults residing in long-term care facilities (LTCFs) since direct OACs (DOACs) were introduced, including trends over time and in people with high-risk comorbidities (prior gastrointestinal bleed and dementia).
methodsA repeated cross-sectional study using the Registry of Senior Australians National Historical Cohort was conducted and included individuals aged ≥ 65 years residing in LTCFs in Australia between 2013 and 2019. Yearly age- and sex-adjusted prevalence of OACs and 95% confidence intervals (CIs) were estimated using generalised estimating equation (GEE) Poisson models and adjusted prevalence ratios (aPRs) were calculated to estimate trends.
resultsIn 500 883 individuals, the prevalence of OAC use increased from 12.2% (95% CI 12.1-12.4) in 2013 to 16.5% (95% CI 16.4-16.7) in 2019 [aPR 1.05 (95% CI 1.05-1.05)]. This was driven by an increase in the use of DOACs, from 2.24% (95% CI 2.19-2.29) to 12.5% (95% CI 12.3-12.6) [aPR 1.25 (95% CI 1.25-1.26)]. Increases in OAC use were also observed in people with prior gastrointestinal bleed, from 12.9% (95% CI 11.8-13.9) to 17.1% (95% CI 16.2-17.9) [aPR 1.05 (95% CI 1.03-1.06)]. The use of OACs increased over the study period for people living with dementia from 9.93% to 12.8% [aPR 1.04 (95% CI 1.04-1.05)], and for people without dementia from 15.7% to 21.7% [aPR 1.06 (95% CI 1.06-1.06)].
conclusionsThis population-based study showed increasing use of OACs among residents of LTCFs, including in higher-risk comorbidity groups, indicating growing confidence in the use of DOACs in these groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.